Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Sycamore Mid Cap Value Equity Gary H. Miller | “Molina Healthcare, Inc. (MOH), a U.S. managed care organization focused on government-sponsored health plans (Medicaid, Medicare, and Marketplace), was the quarter's top contributor. Shares rallied after a strong 1Q26 earnings report refocused investor attention on MOH's core government-sponsored plan business. After a challenging 2025, including a significant 3Q EPS miss, the results signaled that the worst of the medical cost ratio (MCR) deterioration was likely behind the company. Shares also benefited as investors gained greater visibility into the timing and scale of Medicaid spending cuts under the One Big Beautiful Bill Act. Late in the quarter, shares got another lift when CMS released 2025 risk-adjustment transfer data that was viewed favorably for managed care companies. Our thesis for MOH remains intact.” | BULL | Q2 2026 Aug 3, 2026 | View Pitch |
Sycamore Mid Cap Value Equity Gary H. Miller | “The company experienced margin compression due to higher plan utilization and retroactive Medicaid premium adjustments, leading to a quarterly loss. Although near-term guidance disappointed investors, the company is poised for recovery once slow state rate-setting adjusts to current trends.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Meditation Capital Tim Liu | “Toward the end of the year we added to our health insurance investment with a purchase of Molina Healthcare, a Medicaid specialist. Molina generates approximately 75% of premium revenue from Medicaid and has consistently outperformed peers through disciplined cost control and execution. In a year where industry Medicaid profitability is estimated at -2%, Molina still earned a positive 2.3% after-tax margin, reflecting its low-cost operating model and strong success rate in winning and retaining state contracts. The stock trades at roughly 13x 2026 earnings and just 4x our estimate of 2030 earnings, despite management aggressively buying back shares and acquiring struggling plans. We believe prolonged industry stress actually strengthens Molina's competitive position, allowing it to gain share and compound value as margins normalize. BSD Analysis: Molina is a focused operator in Medicaid and Medicare Advantage, serving cost-sensitive populations where execution matters more than brand. The company's underwriting discipline and cost controls have improved dramatically over the past decade. Government reimbursement cycles introduce volatility, but Molina's scale and experience help manage it. Growth is driven by state contract wins rather than market expansion. Margins are thinner than commercial insurance, making operational efficiency critical. When Molina executes well, returns are excellent. This is a high-skill managed-care operator with asymmetric upside on contract performance.” | BULL | Q4 2025 Jan 20, 2026 | View Pitch |
Moon Capital Management David Moon | “We recently initiated a position in Molina Healthcare (MOH), which we believe is a mispriced compounder experiencing transitory margin pressure. The stock traded as high as $300 per share only six months ago; we purchased our shares at approximately $160 in late December. Molina provides managed healthcare services primarily to low-income families and individuals via Medicaid, Medicare and the various state marketplaces established by the 2010 Affordable Care Act (Obamacare). The company is an example of a situation in which the stock price decline has been vastly exacerbated by negative political news—and mostly disconnected from the company's actual business fundamentals. In our view, the market's reaction extrapolates short-term pressures indefinitely and underappreciates both the structural dynamics of Medicaid rate resets and Molina's long track record of operational outperformance versus peers. We see a credible path to 2–3x upside over the next several years as margins normalize and earnings power becomes evident. BSD Analysis: Molina is a focused Medicaid insurer benefiting from scale and cost discipline. Government programs provide volume stability even in downturns. Margin swings reflect state-level reimbursement dynamics. Investors fear policy risk reflexively. Yet Medicaid enrollment remains structurally elevated. Operational execution has improved materially. Cash flow supports balance sheet strength. Molina doesn't need multiple expansion to work. This is public healthcare executed privately.” | BULL | Q4 2025 Jan 15, 2026 | View Pitch |
Harris Associates Concentrated Strategy Tony Coniaris | “Molina Healthcare was a detractor during the quarter. The U.S.-headquartered managed care company's stock price declined after it reported challenging second-quarter results and reduced full year earnings per share guidance. This negative revision was caused by cost pressure in the company's Medicaid and Marketplace businesses. While today's valuation seems to imply that the headwinds impacting Molina are structural, we believe they're attributable to temporary factors and expect a meaningful earnings recovery in the coming years. BSD Analysis: Harris views Molina's weakness as cyclical. With P/E ~12x and strong balance sheet, the stock offers asymmetric upside as Medicaid margins normalize. State renewals and cost controls are likely catalysts for EPS recovery.” | BEAR | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
